Sahm Adrangi is an influential hedge fudge manager who earned his BA of Arts and Economics from Yale University. In 2009 Sahm Adrangi founded Kerrisdale Capital Management LLC. His current active role within the company is Founder and Chief Investment Officer. He launched his company with under $1 million and as of July 2017 his firm manages over $150 Million.
Before Sahm Adrangi founded Kerrisdale Capital Management LLC he was an investment analyst at Longacre Fund Management LLC. Prior to becoming an investment analyst Sahm Adrangi helped people in and out of court with chapter 11 bankruptcy restructuring. Sahm Adrangi’s expertise in analyzing investment data helped him to predict two biotech failures in advance. One biotech failure that Sahm Adrangi was that Bavarian Nordic’s cancer vaccine would fail a study that would render it as nothing more than a placebo. Visit This Page to learn more.
Mr. Adrangi is also stating that another biotech company, Prothena, has manufactured a drug known as NEOD001 that will also be an absolute failure. After analyzing the potential of this drug, Kerrisdale Capital Management LLC has established that is has shown little promise in the phase I/II study. Sahm feels as though both of these drugs show no future in medical advancement and they are currently being traded as a penny stock. Mr. Adrangi is popularly known for short selling and publishing research. Kerrisdale’s research seeks to correct largely thought fallacies about business prospects.
Kerrisdale Capital management LLC shares their research not only on their company website but also on twitter and other investing sites. Sahm has appeared as a guest speaker for CNBS, Bloomberg and has been featured in articles by The Washington Post, Wall Street Journal and the New York Times. He is a known public speaker for investment events such as the Value Investing Conference, Sohn Conference and Traders 4 a Cause. His sound investment analysis has earned him a dedicated following seeking his knowledge and financial guidance.